Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Comparing the Pharmacokinetics of Epoetin Hospira and Epoetin Alfa (Amgen) When Administered Intravenously in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

NCT01170078 is registered in ClinicalTrials.gov with Hospira, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01170078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01170078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Comparing the Pharmacokinetics of Epoetin Hospira and Epoetin Alfa (Amgen) When Administered Intravenously in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
January 31, 2011
Enrollment
107 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure